Citations

Clear

2096 citation(s) found for "Ho, Vincent".

Comparing those Most Satisfied Versus Least Satisfied Following Surgery for Cervical Spondylotic Myelopathy
Chan, Andrew K., Park, Christine , Shaffrey, Christopher I., Gottfried, Oren N., Than, Khoi D., Ef, Bisson, Williamson, Theresa , Bydon, Mohamad, Asher, Anthony L. , Coric, Domagoj , Potts, Eric A., Foley, Kevin T., Wang, Michael Y., Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott, Park, Paul, Upadhyaya, Cheerag, Yen, Chun-Po, Uribe, Juan S., Tumialán, Luis M., Turner, Jay, Chou, Dean, Haid, Regis W., Mummaneni, Praveen V., Chan, Andrew K. , Shaffrey, Christopher I. , Than, Khoi D. , Bisson, Erica F. , Bydon, Mohamad , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Meyer, Scott, Yen, Chun-Po , Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Mummaneni, Praveen V.

Mayo Clinic

Spine | July 3, 2026 | Volume: 51 | Issue: 15 | Pages: 1093-1100

10.1097/brs.0000000000005402 | PMID 42398026 Get It

Study Design. Post hoc analysis of prospectively-collected data. Objective. To identify factors predicting the most (and least) satisfaction following surgery for cervical spondylotic myelopathy (CSM). Summary of Background Data. Patient satisfaction affects long-term outcomes after surgery but the preoperative factors that influence postoperative satisfaction have not been well studied in patients with CSM. Methods. We conducted a post hoc analysis of prospectively-collected data from the Quality Outcomes Database (QOD) CSM registry cohort. Baseline and surgical characteristics were compared for patients with CSM reporting the most [North American Spine Society Satisfaction Score (NASS) 1] and least (NASS 4) satisfaction 24 months postoperatively. A multivariable logistic regression model was constructed using backward stepwise elimination to determine significant predictors of most versus least satisfaction. Twenty-four-month patient-reported outcomes (PROs) were compared. Results. Overall, 1141 patients were prospectively enrolled with 948 (83.1%) reaching 24-month follow-up. Of these, 699 met prespecified inclusion criteria: 610 (87.3%) were most satisfied and 89 (12.7%) were least satisfied. Though there were mean improvements in all 24-month PROs for the most satisfied cohort ( P <0.001), there were no significant improvements in 24-month PROs for the least satisfied cohort ( P >0.05). Using multivariable logistic regression modeling, a preoperative symptom of upper extremity weakness (OR=2.5, P =0.003), subjective myelopathy (OR=2.0, P =0.04), absence of numbness complaints (OR=2.2, P =0.003), symptom duration under 12 months (OR=1.6, P =0.047), Caucasian race (OR=2.3, P =0.001), participation in activities outside of the home (OR=2.0, P =0.04), anterior approach (OR=2.3, P <0.001), and higher baseline quality of life (OR=4.0, P =0.01) were predictive of the most satisfaction. Conclusion. Compared with the least satisfied, those most satisfied following surgery for CSM more often had a preoperative symptom of arm weakness, subjective myelopathy, the absence of numbness complaints, symptom duration under 12 months, higher baseline quality of life, and participation in activities outside of the home. Compared with a posterior approach, an anterior approach was associated with the most satisfaction. Taken together, early surgical treatment--before myelopathic symptoms significantly impact one's quality of life--may be considered to optimize patient satisfaction following CSM surgery.
Growing Heart Valves in Congenital Cardiac Surgery: Mechanisms and Considerations for Tissue-Engineered Heart Valves, Noncryopreserved Homografts, and Partial Heart Transplantation
Lee, Deng Siang , Alexander, Vincent, Vogel, Andrew, Vogel, Andrew D. , Rajab, Taufiek Konrad

Mayo Clinic

Cardiology in Review | July 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001384 | PMID 42385140 Get It

Abstract: Heart valve abnormalities are present in 30% of congenital heart defects. Additionally, there are acquired conditions like rheumatic heart disease. They often require surgery, and in complex cases, valve replacement becomes unavoidable. The current valve replacement options, either mechanical, bioprosthetic, homografts, or autografts, lack key properties for pediatric patient needs: availability, durability, and the ability to grow. Our goal is to review 2 clinically relevant innovations: tissue-engineered heart valves (TEHVs) and partial heart transplantation (PHT). We conducted searches in electronic databases covering the past 25 years using the terms “partial heart transplantation,” “tissue-engineered heart valves,” and their combinations. Decellularized pulmonary homografts outperform cryopreserved homografts and bovine jugular vein conduits in pulmonary valve replacement, showing less stenosis and no infective endocarditis. The European Clinical Study for the Application of Regenerative Heart Valves trial confirmed decellularized pulmonary homograft safety, demonstrating 97.5% freedom from explantation at 5 years. Decellularized aortic homografts showed excellent 97.8% 5-year survival and low endocarditis rates, though increases in transvalvular gradient and regurgitation occurred. Partial heart transplantation uses living valves from donor hearts and accommodates somatic growth. Postoperative immunosuppression in PHT is required but may be limited, as children and valve tissues may possess immune privilege, as evidenced by limited valve injury even in failed orthotopic heart transplants. In a pilot study of 19 infants, with a median follow-up of 26 weeks, increases in annular diameter and leaflet length were observed. Both PHT and TEHVs are promising valve replacement options. While PHT provides a growth-adaptive capability, TEHVs hold the potential for off-the-shelf solutions with minimal immunogenicity.
Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0
Varghese, Chris , Dachs, Nicky , Schamberg, Gabriel , Abell, Thomas, Al‐Haddad, Mohammad, Angeli, Timothy R. , Ayubi, Homira , Bashashati, Mohammad , Bulat, Robert, Calder, Stefan, Cederwall, Christopher Brian, Chang, Bianca W. , Cheng, Leo K. , Clarke, John, Daker, Charlotte , Du, Peng, Erickson, Jon, Eriksson, Sven, Fikree, Asma , Foong, Daphne , Fox, Mark, Goenka, Mahesh, Haidry, R, Holtman, Gerald, Hobson, Anthony , Koloski, Natasha, Kuo, Braden, Law, Mikaela, Levinthal, D., Liu, Joy , Mathur, Prateek , Moshiree, Baharak, Ngo, Catherine, Nguyen, Linda, Oblizajek, Nicholas R. , Parkman, Henry P., Podboy, Alexander, Rezaie, Ali, Simmonds, Sam , Sivakumar, Jonathan , Sirimongkolkasem, Jarongkorn , Sonu, Irene, Stocker, Abigail, Sujka, Joseph, Tack, Jan, Weinstein, Douglas, Windsor, John, Zarate‐Lopez, Natalia, Andrews, Christopher N., O'Grady, Greg, Clarke, John O. , Angeli-Gordon, Timothy R , Chang, Bianca , Cheng, Leo K , Daker, Charlotte , Ghoshal, Uday C , Hasler, W L , Ho, Vincent , Keszthelyi, Daniel , Khalsa, Sahib S , Liu, Joy J , Neshatian, Leila , Oblizajek, Nicholas R , Pandanaboyana, Sanjay , Sharma, Amol , Wang, Xiao Jing , Xu, William , Varghese, Chris , Clarke, J , Schamberg, Gabriel , Al‐Haddad, Mohammad , Ayazi, Shahin , Bulat, Robert, Calder, Stefan , Cederwall, Chris, Du, Peng , Erickson, Jonathan C. , Ghoshal, Uday C. , Hasler, William L. , Hayee, Bu , Ho, Vincent , Huang, I‐Hsuan , Khalsa, Sahib S. , Kuo, Braden , Kunkel, David C. , Law, Mikaela , Levinthal, David J. , Moshiree, Baharak , Neshatian, Leila , Parkman, Henry P. , Podboy, Alexander , Rezaie, Ali , Sonu, Irene S. , Stocker, Abigail, Sujka, Joseph , Tack, Jan , Verdonk, Charles , Wang, Xiao Jing , Wongjarupong, Nicha , Xu, William , Andrews, Christopher N. , Gharibans, Armen A.

Mayo Clinic

Neurogastroenterology & Motility | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70377 | PMID 42381563 Get It

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.
Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report
Samaan, Sami , Devi, Jalpa , VINCENT, Matthew, Coombs, Shannon , Sehgal, Priya , Mohamed, Mouhand , Rai, Victoria , Johnson, Amanda M. , Yarur, Andrés , Barnes, Edward L. , Mohamed, Mouhand F H , Yarur, Andres J , Deepak, Parakkal , Barnes, Edward L , Devi, Jalpa , Sehgal, Priya , Coombs, Shannon , Deepak, Parakkal

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.26355773 | PMID 42396330 Get It

Abstract Background Large language models (LLMs) offer promise for systematic review data extraction, but performance in complex multidisciplinary domains and utility for clinical statement generation remain insufficiently described. Objectives To evaluate Google NotebookLM for AI-assisted data extraction and RAND/UCLA consensus statement generation in a systematic review of IBD, obesity, and cardiometabolic comorbidities. Methods Studies were organized into domain-specific notebooks; structured prompts generated standardized evidence tables. Two independent reviewers validated outputs against full-text articles using a four-category error classification. Cell-level accuracy and critical accuracy (cells free of major factual errors) were the primary metrics; workflow time was compared against a published conventional extraction benchmark. Concordance between AI-generated and expert-finalized statements was assessed. Results Across 57 articles, 1,710 data cells were extracted; 151 (8.83%) were flagged, yielding 91.17% cell-level accuracy. Major factual errors occurred in only 4 cells (0.23%), for a critical accuracy of 99.77%. Most errors were minor omissions (59.6%) or incomplete extractions (30.5%); domain error rates ranged from 7.08% to 11.33%. The pipeline required 17.7 versus a projected 165.1 person-hours (89.3% reduction). PICO-structured prompting generated 70 candidate statements; 58 of 112 finalized panel statements (51.8%) were AI-derived, and 85.7% were retained in the finalized set. Conclusion Google NotebookLM demonstrates feasibility as a primary extraction and synthesis tool in a multidisciplinary systematic review, with extractive incompleteness as the principal limitation and substantial time savings over conventional approaches. Its novel application to RAND/UCLA consensus statement generation extends AI-assisted evidence synthesis to clinical consensus generation workflow.
Acute and Long‐Term EEG and seizure characteristics in new onset refractory status epilepticus (NORSE)
Gilani, Kia , Hanin, Aurélie , Gaspard, Nicolas , Batra, Ayush , Behrndt, Laken, Day, Gregory S. , Demeret, Sophie , Eschbach, Krista , Foreman, Brandon , Gerard, Elizabeth E. , Gopaul, Margaret T., Hantus, Stephen , Cobos‐Hernandez, Carla, Jimenez, Anthony D. , Jongeling, Amy, Kandula, Padmaja , Kang, Peter, Kellogg, Marissa, Kim, Minjee , Farias‐Moeller, Raquel , Morales, M., Pimentel, Cederic M., Ramírez, Alexandra , Taraschenko, Olga , Zhou, Daniel J., Gofton, Teneille E , Haider, Hiba A , Kandula, Padmaja , Farias-Moeller, Raquel , Navarro, Vincent , Steriade, Claude , Struck, A F , Taraschenko, Olga , Wainwright, Mark S , Hirsch, Lawrence J , Yoo, Ji Yeoun , Eschbach, Krista , Gaspard, Nicolas , Day, Gregory S , Batra, Ayush , Hanin, Aurelie , Foreman, Brandon , Gerard, Elizabeth E , Kim, Minjee , Gofton, Teneille , Gopaul, Margaret , Haider, Hiba A. , Jongeling, Amy , Kazazian, Karnig , Kellogg, Marissa , Navarro, Vincent , Steriade, Claude , Struck, Aaron F. , Wainwright, Mark S. , Zhou, Daniel J., Hirsch, Lawrence J. , Yoo, Ji Yeoun

Mayo Clinic

Epilepsia | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70349 | PMID 42359767 Get It

Abstract Objective This study was undertaken to examine acute and chronic electroencephalographic (EEG) and seizure characteristics in new onset refractory status epilepticus (NORSE). Methods Multicenter inpatient and follow‐up clinical and EEG data were analyzed using International League Against Epilepsy definitions and American Clinical Neurophysiology Society (ACNS) EEG terminology. Results Forty‐four patients were included from the Yale NORSE/FIRES Biorepository (median age = 29 years, 33 female, 38 cryptogenic). Nine hundred twenty inpatient EEG days were reviewed (median = 13.5 days/patient). Presenting status epilepticus (SE) types included 24 convulsive SE (CSE), five focal–motor (FMSE), and 15 nonconvulsive (NCSE). Of 39 patients with post discharge follow‐up (median = 14.7 months), 61.5% ( n = 24) had seizures and required more antiseizure medications than seizure‐free patients (median = 4 vs. 1, p < .001). Inpatient EEG captured epileptiform discharges in all and periodic discharges in 38 patients. Seizures were captured in 38 patients: 33 electrographic (11 only electrographic) and 27 electroclinical. Total seizure burden ranged 6.5–29 615.0 min (median = 50.7). Seizures fulfilling ACNS EEG criteria for SE were captured in 20 patients; two had CSE and the remainder NCSE with coma, nine of whom also had FMSE. Inpatient seizure days (median = 50.0 vs. 15.5%, p = .004) and seizure burden (median = 42.9 vs. 0 min, p = .009) were higher in the first half of monitored days. Interictal findings were equally present and did not predict postdischarge seizures, whereas electroclinical seizures (90.9% vs. 45.5%, p = .037), seizure burden (median = 116.8 vs. 32.5 min, p = .045), and proportion of seizure days (36.3% vs. 20.0%, p = .037) did. Among 12 patients with follow‐up EEGs (median = 19.6 months post onset), posterior‐dominant rhythm (PDR) returned in nine; five had periodic discharges, and three had seizure captured. Significance Seizures are most commonly convulsive upon presentation and nonconvulsive or clinically subtle throughout the inpatient course in NORSE. Inpatient seizures, but not interictal abnormalities, occur earlier in the inpatient course and presence of electroclinical seizures, seizure burden, and proportion of seizure days but not interictal findings are associated with postdischarge seizures. Although return of PDR reflects neurological recovery, seizure persistence and EEG abnormalities post‐NORSE are common.
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.
Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement
Xiao, Alexander , Zanwar, Saurabh , Lin, Yi, Kapoor, Prashant , Abdallah, Nadine , Baudi, Francis, Dingli, David, Gertz, Morie A. , Gonsalves, Wilson I, Hayman, Suzanne R. , Kourelis, Taxiarchis , Tan, Melinda SY, Warsame, Rahma , Rajkumar, S Vincent, Kumar, Shaji , Dingli, David , Buadi, Francis K. , Lin, Yi , Lin, Yi , Buadi, Francis K , Binder, Moritz , Dispenzieri, Angela , Dingli, David , Gertz, Morie A , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Siddiqui, Mustaqeem A , Tan, Melinda , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Xiao, Alexander H , Binder, Moritz , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Muchtar, Eli , Siddiqui, Mustaqeem , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: 10 | Issue: 17 | Pages: 5828-5833

10.1182/bloodadvances.2026020668 | PMID 42348786 Get It

Abstract Extramedullary disease (EMD) is increasingly recognized in relapsed/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.
Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study
Muller, David W. , Duncan, AM, Sorajja, Paul, Dahle, Gry , Babaliaros, Vasilis, Lubos, Edith, Badhwar, Vinay , Denti, Paolo, Eng, Marvin H. , Grayburn, Paul, Bethea, Brian, Walters, Darren, Nickenig, Georg, As, Petronio, Thourani, Vinod H, Mumtaz, Mubashir, Dumonteil, Nicolas, Jf, Obadia, Kapadia, S R, Guerrero, Mayra E, Medeiros, Ricardo de, McNutt, Robert, Nie, Hong , Chuang, Michael, Blanke, Philipp, Conradi, Lenard, Duncan, Alison , Muller, David W M , Donal, Erwan , Modine, Thomas , Sorajja, Paul , Babaliaros, Vasilis , Denti, Paolo , Grayburn, Paul , Bethea, Brian, Walters, Darren, Donal, Erwan , Thourani, Vinod H. , Mumtaz, Mubashir , Modine, Thomas , Dumonteil, Nicolas, Guerrero, Mayra , Blanke, Philipp , Conradi, Lenard

Mayo Clinic

ESC Heart Failure | June 25, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.1093/eschf/xvag175 | PMID 42363737 Get It

Abstract Aims Transcatheter mitral valve replacement (TMVR) with the Tendyne Mitral Valve System is a treatment option for patients with severe symptomatic mitral regurgitation (MR) unsuitable for conventional mitral valve surgery or transcatheter edge-to-edge repair (TEER). This study sought to evaluate the safety and effectiveness of TMVR through 5-year follow-up. Methods and Results The Tendyne Expanded Clinical Study is a prospective, single-arm, multicentre study that enrolled patients between November 2014 and June 2020. The study enrolled 191 patients (mean age 74.1 ± 8.0 years, 62.8% male, 70.2% New York Heart Association Class (NYHA) class III/IV, 88.5% secondary MR), of whom 186 (97.4%) underwent TMVR with Tendyne. MR grade decreased from ≥3+ in 99.5% patients at baseline to grade ≤1+ in 95.3% at 5 years. In those patients surviving to 5 years (n = 49), durable symptomatic improvement was evidenced by 73.5% patients being in NYHA class I/II at 5 years. The Kansas City Cardiomyopathy Questionnaire overall summary score increased from 48.5 ± 22.5 points at baseline to 67.6 ± 21.5 points at 5 years. Serious adverse events that occurred through 5 years included life-threatening bleeding (11.5%), fatal bleeding (2.6%), renal insufficiency/failure (28.8%), endocarditis (7.3%), device thrombosis (5.8%), and new onset atrial fibrillation (13.1%). No structural device degeneration or device embolism occurred through 5 years. Conclusions The Tendyne TMVR was effective at achieving immediate and sustainable elimination of MR, which was associated with symptomatic improvement and absence of structural valve degeneration in a high-risk cohort over 5 years. These findings support TMVR with the Tendyne System as an alternative for patients with appropriate mitral valve anatomy and symptomatic secondary MR unsuitable for mitral surgery or TEER.
Abstract A049: Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes
Thakkar, Bijal, Wilson, Ashley , Henderson, Jared, Ayers, Amy, Borgschatz, Sara, Harkins, R. Andrew, Lakra, Priya , Cohen, Jonathon B., Russler-Germain, David, Vega, Francisco, Chapman, J., Inghirami, Giorgio, Lossos, Izidore S. , Koff, Jean L., Nze, Chijioke, Martin, Peter, Syrbu, Sergei, Vij, Kiran, Flowers, Christopher R. , Novak, Anne J., Chihara, Dai, Sakata-Yanagimoto, Mamiko, Tobin, Joshua, Green, M, Abe, Yoshiaki , Kizhakeyil, Atish , Feldman, Andrew L. , Henderson, Jared M. , Ayers, Amy , Harkins, R. Andrew , Kaji, Daisuke , Cohen, Jonathon B. , Mou, Eric , Inghirami, Giorgio , Casulo, Carla , Koff, Jean L. , Nze, Chijioke , Syrbu, Sergei , Jaye, David L. , Cerhan, James R. , Novak, Anne J. , Burack, Richard , Sakata‐Yanagimoto, Mamiko , Tobin, Joshua W.D. , Li, Xubin

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: A049-A049

10.1158/2643-3249.lymphoma26-a049 Get It

Abstract Recent single-cell transcriptomic studies of follicular lymphoma (FL) have revealed heterogeneity among malignant B (MB) cells and selected components of the tumor microenvironment (TME), but have been constrained by relatively small sample sizes and a lack of spatial context. We performed comprehensive cellular profiling and spatial dissection of over five million cells by integrating single-nucleus RNA sequencing (snRNA-seq) from 182 samples (FL, n = 167; control, n = 15) with single-cell spatial transcriptomics (ST) from 386 samples (FL, n = 365; control, n = 21). After stringent quality control, 1,289,073 and 3,968,427 cells from snRNA-seq and ST data, respectively, were analyzed. Unsupervised clustering of snRNA-seq data identified 58 TME cell subtypes. To extend this classification to the ST dataset, we integrated snRNA-seq and ST data by co-embedding them into a shared principal component space, enabling robust batch correction and cell-type label transfer across modalities. Using this supervised annotation framework, ST data recapitulated 54 TME cell subtypes. MB, proliferating MB (MBprolif), and healthy B (HB) cells were classified using sample-level unsupervised clustering in ST. Macrophages exhibited previously uncharacterized heterogeneity in transcriptomic profiles and spatial distribution. We identified CXCL13-expressing macrophage subtypes with high intra- and peri-follicular abundance, termed follicular macrophages (FMs). Non-negative matrix factorization of intrafollicular cell fractions identified five TME archetypes: FM, follicular stroma, two follicular T, and HB archetypes. The FM archetype was enriched for intrafollicular macrophages, including FMs, and showed a significantly higher proportion of grade 3A/3B cases (53.4%) compared to other archetypes (≤16.5%). It was also associated with a higher frequency of high tumor burden requiring treatment initiation rather than a watch-and-wait (WW) approach. Among patients managed by WW, those with the FM archetype showed significantly shorter event-free survival (EFS) compared to those with non-FM archetypes, whereas this association was not observed among treated patients. The percentage of intrafollicular macrophages (IFMP) showed excellent predictive performance for the FM archetype (area under the curve: 0.90). IFMP calculated in a published multiplex spatial protein imaging dataset from an independent cohort of 242 FL patients validated the associations between high IFMP and both pathology grade 3A/3B and shorter EFS in WW patients. Consistently, spatial neighborhood and cell–cell communication analyses revealed co-localization of FMs and MBprolif cells, forming a distinct niche with activated signaling mediated by FM-derived CXCL13, APRIL, and BAFF. Our integrative multi-modal analysis defines previously unrecognized cellular heterogeneity and spatial architecture in FL and highlights macrophage-enriched follicular ecosystems associated with aggressive clinicopathological features, providing a framework for improved biological understanding and patient management. Citation Format: Yoshiaki Abe, Bijal Thakkar, Atish Kizhakeyil, Ashley Wilson, Andrew L. Feldman, Jared Henderson, Amy Ayers, Sara Borgschatz, R. Andrew Harkins, Priya Lakra, Daisuke Kaji, Jonathon B. Cohen, David Russler-Germain, Eric Mou, Francisco Vega, Jennifer Chapman, Giorgio Inghirami, Carla Casulo, Izidore S. Lossos, Jean L. Koff, Chijioke Nze, Peter Martin, Sergei Syrbu, Kiran Vij, David L. Jaye, James R. Cerhan, Christopher R. Flowers, Anne J. Novak, Richard Burack, Dai Chihara, Mamiko Sakata-Yanagimoto, Joshua Tobin, Xubin Li, Michael R. Green. Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A049.